Insider Selling: Genomic Health, Inc. (NASDAQ:GHDX) CFO Sells 60,000 Shares of Stock

Genomic Health, Inc. (NASDAQ:GHDX) CFO G Bradley Cole sold 60,000 shares of the firm’s stock in a transaction on Monday, August 12th. The stock was sold at an average price of $73.31, for a total transaction of $4,398,600.00. The sale was disclosed in a document filed with the SEC, which is available through this link.

G Bradley Cole also recently made the following trade(s):

  • On Tuesday, July 9th, G Bradley Cole sold 6,471 shares of Genomic Health stock. The stock was sold at an average price of $57.08, for a total transaction of $369,364.68.
  • On Tuesday, June 11th, G Bradley Cole sold 5,000 shares of Genomic Health stock. The stock was sold at an average price of $51.46, for a total transaction of $257,300.00.

Shares of Genomic Health stock traded down $0.20 during trading hours on Wednesday, reaching $74.70. The company’s stock had a trading volume of 759,265 shares, compared to its average volume of 581,840. The business’s 50 day moving average price is $63.20. The company has a current ratio of 5.74, a quick ratio of 5.74 and a debt-to-equity ratio of 0.17. Genomic Health, Inc. has a one year low of $50.77 and a one year high of $92.18. The stock has a market capitalization of $2.74 billion, a PE ratio of 71.17 and a beta of 1.06.

Genomic Health (NASDAQ:GHDX) last posted its quarterly earnings results on Monday, July 29th. The medical research company reported $0.42 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.35 by $0.07. Genomic Health had a net margin of 11.69% and a return on equity of 19.51%. The company had revenue of $114.14 million for the quarter, compared to the consensus estimate of $110.78 million. During the same period last year, the firm posted $0.23 EPS. The company’s revenue for the quarter was up 19.4% on a year-over-year basis. Analysts expect that Genomic Health, Inc. will post 1.5 EPS for the current year.

Several research analysts have weighed in on the stock. Needham & Company LLC lowered shares of Genomic Health from a “strong-buy” rating to a “hold” rating in a report on Tuesday, July 30th. ValuEngine raised shares of Genomic Health from a “hold” rating to a “buy” rating in a report on Saturday, July 27th. Canaccord Genuity lowered shares of Genomic Health from a “buy” rating to a “hold” rating and decreased their price objective for the stock from $77.00 to $72.00 in a report on Tuesday, July 30th. Zacks Investment Research raised shares of Genomic Health from a “hold” rating to a “buy” rating and set a $77.00 price objective for the company in a report on Wednesday, July 31st. Finally, Barclays raised shares of Genomic Health from an “underweight” rating to an “equal weight” rating and raised their price objective for the stock from $45.00 to $72.00 in a report on Tuesday, July 30th. Nine research analysts have rated the stock with a hold rating, two have issued a buy rating and one has given a strong buy rating to the stock. The stock currently has a consensus rating of “Hold” and an average target price of $69.86.

Several institutional investors have recently bought and sold shares of the company. Marshall Wace North America L.P. purchased a new position in shares of Genomic Health in the second quarter worth approximately $1,372,000. Balyasny Asset Management LLC increased its position in shares of Genomic Health by 107.3% in the second quarter. Balyasny Asset Management LLC now owns 37,376 shares of the medical research company’s stock worth $2,174,000 after acquiring an additional 19,342 shares in the last quarter. Mackenzie Financial Corp increased its position in shares of Genomic Health by 593.6% in the second quarter. Mackenzie Financial Corp now owns 34,090 shares of the medical research company’s stock worth $1,983,000 after acquiring an additional 29,175 shares in the last quarter. Invesco Ltd. increased its position in shares of Genomic Health by 316.4% in the second quarter. Invesco Ltd. now owns 687,787 shares of the medical research company’s stock worth $40,009,000 after acquiring an additional 522,627 shares in the last quarter. Finally, Vanguard Group Inc. increased its position in shares of Genomic Health by 12.1% in the second quarter. Vanguard Group Inc. now owns 2,828,265 shares of the medical research company’s stock worth $164,520,000 after acquiring an additional 305,047 shares in the last quarter. Institutional investors own 95.63% of the company’s stock.

Genomic Health Company Profile

Genomic Health, Inc, a healthcare company, provides clinically actionable genomic information to personalize cancer treatment decisions in the United States and internationally. The company develops and commercializes genomic-based clinical laboratory services that analyze the underlying biology of cancer, which allows physicians and patients to make individualized treatment decisions.

Featured Story: Holder of Record

Insider Buying and Selling by Quarter for Genomic Health (NASDAQ:GHDX)

Receive News & Ratings for Genomic Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genomic Health and related companies with MarketBeat.com's FREE daily email newsletter.